By Craig Morgan NZCS, MBA (Hons), PMP, goBalto, Inc.
With thousands of investigational pharmaceuticals, biologics, and medical devices in clinical trials, there is intense pressure to speed them along so the more promising candidates will come to market sooner. Patients across the globe are waiting for these new therapies, but complicated study protocols, globalization, and paper-based methods of conducting trials continue to delay market entry. Fortunately, the current approach to clinical trials, widely acknowledged as complex and slow, has been driving stakeholders to embrace cloud-based solutions to bring efficiencies to the process, but one key bottleneck—study start-up (SSU)—has been largely overlooked. Current thinking looks to an improved SSU process as holding great promise for accelerating clinical trials.